Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2021-02-17
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
JTT-662 administered once daily for 28 days in subjects with Type 2 diabetes mellitus (T2DM)
who are receiving metformin monotherapy